Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

In large early Parkinson's trial, one dose worked but another did not. Review will show how results from innovative trial will be received by FDA.
Advertisement

Related Content

Data For Teva's Azilect Not Good Enough For Claim Of Slowing Parkinson's Progression, FDA Panel Says
Data For Teva's Azilect Not Good Enough For Claim Of Slowing Parkinson's Progression, FDA Panel Says
Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
Teva Targets $113 Billion In Branded Sales With Dozens Of Pending Applications
Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks

Topics

Advertisement
UsernamePublicRestriction

Register

PS072582

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel